Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05635643 · ClinicalTrials.gov registry record · Phase 1

Study of CHS-114 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma, sponsored by Coherus Oncology.

Recruiting
Registry status
Phase 1
Development phase
87
Enrollment target
16
Study locations

NCT05635643: Recruiting Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma, sponsored by Coherus Oncology.

NCT05635643 is a Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 87 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05635643, a Phase 1 study of Advanced Solid Tumor and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Coherus Oncology.

RECRUITING
Registry status
Phase 1
Development phase
87 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Primary Outcome

Evaluation of rate of DLT of CHS-114 as a monotherapy, or in combination with toripalimab

Conditions Studied

Advanced Solid Tumor Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG CHS-114
  • DRUG toripalimab

Study Locations (16)

California

  • Hoag Memorial Hospital - Newport Beach
  • FOMAT Medical Research - Oxnard
  • Stanford Cancer Center - Palo Alto

Michigan

  • University of Michigan - Ann Arbor
  • Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Detroit

Florida

  • SCRI Lake Nona DDU (FL Cancer Specialists) - Orlando

Georgia

  • Emory Winship Cancer Institute - Atlanta

Illinois

  • Hope & Healing Cancer Services - Hinsdale

Kentucky

  • University of Louisville - Louisville

Maryland

  • University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2022-12-15
Est. Completion 2027-01-01
Phase Phase 1
Coherus Oncology

15 total trials

What NCT05635643 shows while recruiting

NCT05635643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which CHS-114 is the first listed.

NCT05635643 lists 16 locations in 13 states (California, Michigan, Florida).

Frequently Asked Questions

What is clinical trial NCT05635643 about?

NCT05635643 is a clinical study titled "Study of CHS-114 in Participants With Advanced Solid Tumors". This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

What is the current status of trial NCT05635643?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2022-12-15. Estimated completion is 2027-01-01.

What conditions does trial NCT05635643 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05635643?

The interventions under investigation include: CHS-114 (DRUG), toripalimab (DRUG).

Who is sponsoring clinical trial NCT05635643?

This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05635643 being conducted?

This trial has 16 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05635643's enrollment target sits among peer trials

87 128th of 189 higher than 61 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05635643

Source: ClinicalTrials.gov NCT05635643, the US trial registry maintained by the National Library of Medicine. NCT05635643 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.